Study of Efepoetin Alfa for anemia in kidney dialysis patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have stage 5 chronic kidney disease and have been on hemodialysis for at least 12 weeks.
- Your average hemoglobin level (a measure of red blood cells) should be between 9.0 and 12.0 g/dL.
- You must have enough iron in your blood, as shown by specific lab tests (ferritin at least 100 ng/mL and transferrin saturation at least 20%).
- You must be on a stable dose of an erythropoiesis-stimulating agent (ESA) for at least 6 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two similar medicines that help your body make red blood cells. It is for people with advanced chronic kidney disease who are on dialysis, and aims to see if the study medicine works as well as the standard one.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
This study looks at how well erythropoietin (a drug that helps your body make red blood cells) works for people with end-stage kidney disease who are on regular hemodialysis. It also checks if metabolic syndrome (a group of conditions like high blood sugar, high blood pressure, and extra belly fat) affects how well this drug works.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.